BMEA — Biomea Fusion, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840439 ·
Last close
$1.20
Market Cap
$86.76M
52W High
$2.24
52W Low
$1.07
ADV30
1,102,942
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | — | — | 46,385,000 | 44,693,000 | 27,666,000 |
| Dec 2025 | 0 | — | -11,719,000 | 4,612,000 | 58,572,000 | 55,812,000 | 29,020,000 |
| Sep 2025 | 0 | — | -18,600,000 | -16,407,000 | 55,187,000 | 46,642,000 | 39,568,000 |
| Jun 2025 | 0 | — | -21,276,000 | -20,740,000 | 73,163,000 | 56,224,000 | 45,653,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,373,000
Investing CF
$550,000
Financing CF
$64,652,000
CapEx
$-268,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.75
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-449,048,000
Inventory
—
Receivables
$22,000
ST Investments
—
EBIT TTM
$-81,307,000
Pretax Income TTM
$-61,797,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -81,307,000 | -61,797,000 | 58,572,000 | 29,020,000 | — | -70,371,000 |
| Dec 2024 | 0 | -144,070,000 | -138,426,000 | 79,938,000 | 28,365,000 | — | -119,894,000 |
| Dec 2023 | 0 | -126,135,000 | -117,255,000 | 199,927,000 | 30,690,000 | — | -96,592,000 |
| Dec 2022 | 0 | -83,634,000 | -81,828,000 | 129,307,000 | 20,768,000 | — | -62,417,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.10
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.20 · call volume: 16 · put volume: 261
Expected Move to 2026-07-17:
±$0.80
(66.67%) —
implied range
$0.40 –
$2.00
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | $87.50M | $0.18 | — |
| RANI | Rani Therapeutics Holdings, Inc. | $86.00M | $0.77 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $85.97M | $1.25 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $84.06M | $5.61 | — |
| ELTX | Elicio Therapeutics, Inc. | $89.90M | $4.71 | — |
News headlines (Yahoo Finance, 1h cache)
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
2026-06-05 23:32 · Yahoo
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
2026-06-03 12:00 · Yahoo
Biomea Fusion to Participate at Upcoming Investor Conferences
2026-05-12 20:05 · Yahoo
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-11 20:54 · Yahoo
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
2026-05-05 21:50 · Yahoo
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026
2026-05-05 20:20 · Yahoo
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
2026-04-28 20:31 · Yahoo
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
2026-04-27 21:37 · Yahoo
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
2026-03-31 11:00 · Yahoo
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
2026-03-30 21:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.